TY - JOUR
KW - Humans
KW - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects
KW - *Diabetes Mellitus, Type 2/drug therapy
KW - Male
KW - Female
KW - *Glucagon-Like Peptide-1 Receptor/agonists
KW - *Cardiovascular Diseases/prevention & control/epidemiology/mortality
KW - Middle Aged
KW - Aged
KW - *Drug Therapy, Combination
KW - Incidence
KW - *Hypoglycemic Agents/therapeutic use/adverse effects
KW - United Kingdom/epidemiology
KW - Cohort Studies
KW - Glucagon-like peptide-1 receptor agonists
AU - N. Simms-Williams
AU - N. Treves
AU - H. Yin
AU - S. Lu
AU - O. Yu
AU - R. Pradhan
AU - C. Renoux
AU - S. Suissa
AU - L. Azoulay
AD - Institute of Applied Health Research College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Department of Clinical Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Departments of Neurology and Neurosurgery, Jewish General Hospital, Montreal, QC, Canada.
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada laurent.azoulay@mcgill.ca.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.
AN - 38663919
BT - Bmj
C2 - PMC11043905 at https://www.icmje.org/disclosure-of-interest/ and declare: this study was funded by the Canadian Institutes of Health Research; LA received speaking and consulting fees from Pfizer and Roche for work unrelated to this project; SS attended scientific advisory committee meetings for AstraZeneca, Atara, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer, and Seqirus and received speaking fees from Boehringer-Ingelheim and Novartis; no other relationships or activities that could appear to have influenced the submitted work.
DO - 10.1136/bmj-2023-078242
DP - NLM
ET - 2024/04/26
LA - eng
N1 - 1756-1833
Simms-Williams, Nikita
Treves, Nir
Yin, Hui
Lu, Sally
Yu, Oriana
Pradhan, Richeek
Renoux, Christel
Suissa, Samy
Azoulay, Laurent
Orcid: 0000-0001-5162-3556
Journal Article
Research Support, Non-U.S. Gov't
England
BMJ. 2024 Apr 25;385:e078242. doi: 10.1136/bmj-2023-078242.
PY - 2024
SN - 0959-8138 (Print)
0959-8138
EP - e078242
T2 - Bmj
TI - Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
VL - 385
ER -